Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES

• Status: Unknown status
• Trial end date: 2020-07-07
• Target enrollment: 0
• Participant gender: All

Summary

To compare the efficacy and safety of clopidogrel monotherapy versus aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with DES.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Subject must be at least 20 years of age.

• Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

• Patients undergoing successful PCI

Exclusion Criteria:

• Hemodynamic instability or cardiogenic shock

• Active bleeding

• Known hypersensitivity or contraindication to study medications

• Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study

• Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment).

• DES implantation within 12 months before index procedure